Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor

　　1.Sole Formal Contraindication:No Strong CYP3A Inducers

　　The prescribing information lists only one formal contraindication for lorlatinib:concurrent use with strong CYP3A inducers is prohibited due to the risk of severe hepatotoxicity.Before initiating lorlatinib,NSCLC patients must confirm whether they are taking such agents and discontinue them as required.

　　2.Six Major Safety Risks Requiring Vigilance

　　Beyond the contraindication,clinicians should monitor for six categories of adverse reactions:

　　CNS adverse reactions:Lorlatinib penetrates the CNS and may cause cognitive changes,mood disturbances,psychiatric symptoms,speech disorders,sleep abnormalities,and seizures.Long-term users require particular attention.

　　Dyslipidemia:Cholesterol and triglyceride elevations may occur;lipid profiles should be monitored during extended therapy.

　　Cardiac conduction issues:Including atrioventricular block.Patients with pre-existing cardiac disease or those taking drugs affecting conduction are at higher risk.

　　Interstitial lung disease/pneumonitis:New cough,dyspnea,or fever warrants prompt evaluation for drug-related lung injury.

　　Hypertension:Blood pressure may rise during treatment.Long-term patients should monitor vital signs alongside tumor markers.

　　Hyperglycemia and other metabolic abnormalities:Observe in the context of patients'baseline conditions and concomitant medications.

　　3.Special Population Precautions

　　Lorlatinib carries an embryo-fetal toxicity risk and may harm the fetus if used during pregnancy.Individuals of reproductive potential should use effective contraception during treatment and for a period after discontinuation.